(Reuters) -Intercept Pharmaceuticals said on Thursday it is voluntarily withdrawing its liver disease treatment from the U.S. market following a request from the Food and Drug Administration.
The U.S. FDA said in December it had identified cases of serious liver injury among patients being treated with the drug, Ocaliva, chemically known as obeticholic acid.
The drug treats primary biliary cholangitis, a rare disease that causes inflammation of small bile ducts in the liver and can eventually destroy them.
The FDA has also placed a clinical hold on all Intercept clinical trials conducted in the U.S. involving obeticholic acid, the company said on Thursday.
(Reporting by Sneha S K; Editing by Shreya Biswas)
Brought to you by www.srnnews.com
